These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 30216622

  • 1. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
    Hackett G, Cole N, Mulay A, Strange RC, Ramachandran S.
    BJU Int; 2019 Mar; 123(3):519-529. PubMed ID: 30216622
    [Abstract] [Full Text] [Related]

  • 2. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
    Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S.
    Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
    [Abstract] [Full Text] [Related]

  • 3. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins.
    Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S.
    Int J Clin Pract; 2016 Mar; 70(3):244-53. PubMed ID: 26916621
    [Abstract] [Full Text] [Related]

  • 4. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study.
    Magnussen LV.
    Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673384
    [Abstract] [Full Text] [Related]

  • 5. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S.
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [Abstract] [Full Text] [Related]

  • 6. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G.
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [Abstract] [Full Text] [Related]

  • 7. Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups.
    Ramachandran S, Hackett GI, Strange RC.
    Andrology; 2020 Sep; 8(5):1222-1232. PubMed ID: 32384175
    [Abstract] [Full Text] [Related]

  • 8. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A, Blast Study Group.
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [Abstract] [Full Text] [Related]

  • 9. 12-month observation of testosterone replacement effectiveness in a general population of men.
    Miner MM, Bhattacharya RK, Blick G, Kushner H, Khera M.
    Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
    [Abstract] [Full Text] [Related]

  • 10. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes.
    Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH.
    Eur J Endocrinol; 2013 Dec; 169(6):725-33. PubMed ID: 23999642
    [Abstract] [Full Text] [Related]

  • 11. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports.
    Saad F, Yassin A, Almehmadi Y, Doros G, Gooren L.
    Aging Male; 2015 Dec; 18(3):164-8. PubMed ID: 26075537
    [Abstract] [Full Text] [Related]

  • 12. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Blick G, Khera M, Bhattacharya RK, Kushner H, Miner MM.
    Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
    [Abstract] [Full Text] [Related]

  • 13. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS.
    JAMA; 2006 Nov 15; 296(19):2351-61. PubMed ID: 17105798
    [Abstract] [Full Text] [Related]

  • 14. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC, Wu F, Behre HM, Porst H, Meuleman EJH, Maggi M, Romero-Otero J, Martinez-Salamanca JI, Jones TH, Debruyne FMJ, Kurth KH, Hackett GI, Quinton R, Stroberg P, Reisman Y, Pescatori ES, Morales A, Bassas L, Cruz N, Cunningham GR, Wheaton OA, RHYME Investigators.
    J Sex Med; 2017 Sep 15; 14(9):1104-1115. PubMed ID: 28781213
    [Abstract] [Full Text] [Related]

  • 15. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
    Yassin A, Almehmadi Y, Saad F, Doros G, Gooren L.
    Clin Endocrinol (Oxf); 2016 Jan 15; 84(1):107-14. PubMed ID: 26331709
    [Abstract] [Full Text] [Related]

  • 16. Symptom report and treatment experience of hypogonadal men with and without type 2 diabetes in a United States health plan.
    Shortridge EF, Polzer P, Donga P, Wade RL.
    Int J Clin Pract; 2015 Jul 15; 69(7):783-90. PubMed ID: 25854747
    [Abstract] [Full Text] [Related]

  • 17. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial.
    Ng Tang Fui M, Hoermann R, Prendergast LA, Zajac JD, Grossmann M.
    Int J Obes (Lond); 2017 Mar 15; 41(3):420-426. PubMed ID: 28028318
    [Abstract] [Full Text] [Related]

  • 18. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
    Hackett G.
    Sex Med Rev; 2019 Jul 15; 7(3):476-490. PubMed ID: 30803918
    [Abstract] [Full Text] [Related]

  • 19. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
    Kaplan AL, Lenis AT, Shah A, Rajfer J, Hu JC.
    J Sex Med; 2015 Feb 15; 12(2):374-80. PubMed ID: 25496237
    [Abstract] [Full Text] [Related]

  • 20. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schröder FH, Jones TH, Porst H, Hackett G, Wheaton OA, Martin-Morales A, Meuleman E, Cunningham GR, Divan HA, Rosen RC, RHYME Investigators.
    BJU Int; 2017 Feb 15; 119(2):216-224. PubMed ID: 27409523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.